doi:

DOI: 10.3724/SP.J.1206.2012.00034

Progress in Biochemistry and Biophysics (生物化学与生物物理进展) 2012/39:8 PP.721-725

Role of Neprilysin in The Pathogenesis of Alzheimer′s Disease*


Abstract:
Deposition of β amyloid (Aβ) in hippocampus is a crucial progression in the pathophysiology of Alzheimer′s disease (AD). Decreasing its formation and/or increasing its clearance have become a focus of AD therapy. As compared with increased Aβ production, decreased Aβ degradation plays a more important role in AD pathogenesis. Although Aβ can be cleared through transportation to the blood and cerebral spinal fluid pathway, the so-called "vascular system", most Aβ peptide was degraded to small molecules by a kind of protease called Aβ degrading enzyme represented by neprilysin (NEP). In the olderly, mild cognitive impairment and AD patients, the NEP activity is decreased, and the decreased NEP activity is correlated with Aβ content in brain and cognitive function impairment. If NEP activity was increased to degrade Aβ, it may inhibit AD progression and even have disease-modifying potential in AD and NEP thus may behave as a potential drug target for AD therapy.

Key words:Alzheimer′s disease (AD), Aβ degrading enzymes (ADEs), neprilysin (NEP), β amyloid (Aβ)

ReleaseDate:2014-07-21 16:19:13

Funds:This work was supported by a grant from Henan Science and Technology Program(112102310684)



[1] He R Q, Lu J, Miao J Y. Formaldehyde stress. Sci China Life Sci, 2010, 53(12): 1399-1404

[2] Tong Z Q, Zhang J L, Luo W H, et al. Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol Aging, 2011, 32(1): 31-41

[3] Zhou J W. Recent progress in neurodegenerative disorder research in China. Sci China Life Sci, 2010, 53(3): 348-355

[4] Liu Y, Qiang M, Wei Y, et al. A novel molecular mechanism for nitrated α-synuclein-induced cell death. J Mol Cell Biol, 2011, 3(4): 239-249

[5] Naqvi S H, 王维山, 苗君叶, 等. 甲醛诱导Tau蛋白形成“孔道样”聚集结构. 生物化学与生物物理进展, 2010, 37(11): 1195- 1203 Naqvi S H, Wang W S, Miao J Y, et al. Prog Biochem Biophys, 2010, 37(11): 1195-1203

[6] Zhang X H, Poo M M. Progress in neural plasticity. Sci China Life Sci, 2010, 53(3): 322-329

[7] Luo Z G. Synapse formation and remodeling. Axon guidance and neuronal migration research in China. Sci China Life Sci, 2010, 53(3): 315-321

[8] Zhang M, Zhao Z M, He L, et al. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci, 2010, 53(1): 112-124

[9] Sun P, Zhang Q, Han J Y, et al. TLR4 signaling induced TLR2 expression in the process of mimic cerebral ischemia/reperfusion in vitro. Sci China Life Sci, 2010, 53(2): 223-228

[10] Wang Y Z, Xu T L. Ion channels in neuronal survival. Sci China Life Sci, 2010, 53(3): 342-347

[11] 徐淑君, 刘桂兰. β淀粉样蛋白导致的线粒体损伤研究进展. 生物化学与生物物理进展, 2010, 37(6): 589-593 Xu S J, Liu G L. Prog Biochem Biophys, 2010, 37(6): 589-593

[12] Luo Y F, Zhang J, Liu N Q, et al. Copper ions influence the toxicity of β-amyloid(1-42) in a concentration-dependent manner in a Caenorhabditis elegans model of Alzheimer′s disease. Sci China Life Sci, 2011, 54(6): 527-534

[13] Mulder S D, Veerhuis R, Blankenstein M A, et al. The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Exp Neurol, 2012, 233(1): 373-379

[14] Mawuenyega K G, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 2010, 330(6012): 1774

[15] Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Aβ42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med, 2000, 6(2): 143-150

[16] Takaki Y, Iwata N, Tsubuki S, et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain. J Biochem, 2000, 128(6): 897-902

[17] Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. Science, 2001, 292(5521): 1550-1552

[18] Mouri A, Zou L B, Iwata N, et al. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid β and impairment of learning and memory. Behav Brain Res, 2006, 168(1): 83-91

[19] Poirier R, Wolfer D P, Welzl H, et al. Neuronal neprilysin overexpression is associated with attenuation of Aβ-related spatial memory deficit. Neurobiol Dis, 2006, 24(3): 475-483

[20] Liu Y, Studzinski C, Beckett T, et al. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther, 2009, 17(8): 1381-1386

[21] Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett, 2003, 350(2): 113-116

[22] Caccamo A, Oddo S, Sugarman M C, et al. Age and region- dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol Aging, 2005, 26(5): 645-654

[23] Wang R, Wang S, Malter J S, et al. Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells. J Neurochem, 2009, 108(4): 1072-1082

[24] Hellstrom-Lindahl E, Ravidb R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer′s disease and normal brain: Inverse correlation with Aβ levels. Neurobiol Aging, 2008, 29(2): 210-221

[25] Wang S, Wang R, Chen L, et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem, 2010, 115(1): 47-57

[26] Huang S M, Mouri A, Kokubo H, et al. Neprilysin-sensitive synapse-associated Aβ oligomers impair neuronal plasticity and cognitive function. J Biol Chem, 2006, 281(26): 17941-17951

[27] Leung K K, Shen K K, Barnes J, et al. Increasing power to predict mild cognitive impairment conversion to Alzheimer′s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv, 2010, 13(Pt2): 125-132

[28] Albert M S, DeKosky S T, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer′s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 270-279

[29] McKhann G M, Knopman D S, Chertkow H, et al. The diagnosis of dementia due to Alzheimer′s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 263-269

[30] Mattsson N, Portelius E, Rolstad S, et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis, 2012, 30(4): 767-778

[31] Rodrigue K M, Kennedy K M, Devous M D Sr, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology, 2012, 78(6): 387-395

[32] Chételat G, Villemagne V L, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology, 2012, 78(7): 477-484

[33] Holler C J, Webb R L, Laux A L, et al. BACE2 expression increases in human neurodegenerative disease. Am J Pathol, 2012, 180(1): 337-350

[34] Austin B P, Nair V A, Meier T B, et al. Effects of hypoperfusion in Alzheimer′s disease. J Alzheimers Dis, 2011, 26(Suppl 3): 123-133

[35] Prasad K, Wiryasaputra L, Ng A, et al. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer′s disease in a clinic cohort. Dement Geriatr Cogn Disord, 2011, 31(6): 431-434

[36] Huang J Y, Hafez D M, James B D, et al. Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis, 2012, 28(2): 433-441

[37] Maruyama M, Higuchi M, Takaki Y, et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol, 2005, 57(6): 832-842

[38] SaitoT, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation. Nat Med, 2005, 11(4): 434-439

[39] Saiz-Sanchez D, Ubeda-Banon I, de la Rosa-Prieto C, et al. Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Exp Neurol, 2010, 223(2): 347-350

[40] Sandoval K E, Farr S A, Banks W A, et al. Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular Aβ(1-42) trimers. Eur J Pharmacol, 2012, 683(1-3): 116-124

[41] Liang K, Yang L, Yin C, et al. Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J Biol Chem, 2010, 285(2): 935-942

[42] Belyaev N D, Nalivaeva N N, Makova N Z, et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer's disease. EMBO Rep, 2009, 10(1): 94-100

[43] Pardossi-Piquard R, Petit A, Kawarai T, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron, 2005, 46(4): 541-554

[44] Bauer C, Pardossi-Piquard R, Dunys J, et al. γ-Secretase-mediated regulation of neprilysin: Influence of cell density and aging and modulation by imatinib. J Alzheimers Dis, 2011, 27(3): 511-520

[45] Nalivaeva N N, Belyaev N D, Lewis D I, et al. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J Mol Neurosci, 2012, 46(3): 569-577

[46] Qing H, He G, Ly P T, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer′s disease mouse models. J Exp Med, 2008, 205(12): 2781-2789

[47] Huang H, Bihaqi S W, Cui L, et al. In vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysin. Neurotoxicology, 2011, 32(3): 300-306

[48] Wang Z, Yang D, Zhang X, et al. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One, 2011, 6(4): e19229

[49] Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer′s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov, 2011, 10(9): 698-712